Adial Pharmaceuticals Targets $40B Addiction Market
Adial Pharmaceuticals acquires patent for genetic diagnostic tool to identify patients who may respond well to their lead drug AD04, ...
- Latest
- Trending
Adial Pharmaceuticals acquires patent for genetic diagnostic tool to identify patients who may respond well to their lead drug AD04, ...
Protagenic Therapeutics achieves milestone in Phase I trial for PT00114, a compound for treating stress-related neuro-psychiatric disorders. No adverse reactions ...
Sosei Group Corporation announces operational activities and consolidated results, including significant investment, marketing approval, and partnerships. Despite revenue decrease, the ...
Regeneron Pharmaceuticals, a leading biopharmaceutical company, is gaining recognition for its innovative approach and strong financial performance. With a diverse ...
Connect Biopharma has appointed James Zuie-chin Huang to its Board of Directors. Huang brings over 30 years of biotech experience ...
BioVaxys Technology Corp. finalizes agreement to acquire IMV Inc.'s immunotherapy technology portfolio, expanding its cancer vaccine portfolio and positioning itself ...
YS Biopharma raises concerns about the validity of an extraordinary general meeting called by shareholders. The company also faces financial ...
Kintara Therapeutics has launched a clinical trial for REM-001, a promising treatment for cutaneous metastatic breast cancer. The trial aims ...
Diamondback Energy and Endeavor Energy Resources are set to merge in a $26 billion deal, boosting Diamondback shares. Other companies ...
Tonix Pharmaceuticals receives FDA clearance for its OASIS trial, evaluating the efficacy of TNX-102 SL in treating acute stress reactions ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.